Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

The cyclin D‐CDK4/6‐INK4‐Rb pathway is frequently dysregulated in cancers. Ribociclib, an orally available, selective CDK4/6 inhibitor, showed preliminary clinical activity in a phase I study in the USA and Europe for patients with solid tumors and lymphomas. The present study aimed to determine the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2018-01, Vol.109 (1), p.193-198
Hauptverfasser:	Doi, Toshihiko, Hewes, Becker, Kakizume, Tomoyuki, Tajima, Takeshi, Ishikawa, Norifumi, Yamada, Yasuhide
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult advanced solid tumors Aminopyridines - administration & dosage Aminopyridines - adverse effects Aminopyridines - pharmacology Antitumor activity Breast cancer Cancer therapies Cell cycle Chemotherapy Clinical trials Cyclin D Cyclin-dependent kinase 4 Cyclin-dependent kinase inhibitors Disease Progression dose escalation Drug Administration Schedule Esophagus Female Humans INK4 protein Japan Japanese patients Kinases Laboratories Lymphoma Male Maximum Tolerated Dose Metabolism Metabolites Middle Aged Neoplasms - drug therapy Original Patients phase 1 Purines - administration & dosage Purines - adverse effects Purines - pharmacology ribociclib Sample Size Solid tumors Studies Targeted cancer therapy Toxicity Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!